tetano
Editor, Senior Moderator
Res Pract Thromb Haemost
. 2021 Feb 8;5(2):292-295.
doi: 10.1002/rth2.12485. eCollection 2021 Feb.
Vascular thromboembolic events following COVID-19 hospital discharge: Incidence and risk factors
Harish Eswaran[SUP] 1 [/SUP], Jamie A Jarmul[SUP] 2 [/SUP], Amy W Shaheen[SUP] 3 [/SUP], David Meaux[SUP] 2 [/SUP], Tristan Long[SUP] 2 [/SUP], Derek Saccoccio[SUP] 2 [/SUP], Stephan Moll[SUP] 4 [/SUP]
Affiliations
Abstract
Background: Coronavirus disease 2019 (COVID-19) is associated with high rates of thromboembolic events in hospitalized patients. It remains to be determined if this risk persists following hospital discharge.
Methods: We conducted a retrospective cohort study of outpatients recently hospitalized for COVID-19 to determine the incidence of vascular thromboembolic events within 30 days of discharge. We investigated the risk factors associated with these events, including intensive care admission, age, and anticoagulation.
Results: Among 447 patients hospitalized for COVID-19, 2.0% experienced a vascular thromboembolic event within 30 days of discharge. No risk factor variable was significantly associated with an increased risk for these events.
Conclusions: The incidence of vascular thromboembolic events following hospital discharge for COVID-19 is low. These findings suggest against the routine use of postdischarge thromboprophylaxis in patients with COVID-19.
Keywords: COVID?19; anticoagulant; discharge; outpatients; thromboembolism.
. 2021 Feb 8;5(2):292-295.
doi: 10.1002/rth2.12485. eCollection 2021 Feb.
Vascular thromboembolic events following COVID-19 hospital discharge: Incidence and risk factors
Harish Eswaran[SUP] 1 [/SUP], Jamie A Jarmul[SUP] 2 [/SUP], Amy W Shaheen[SUP] 3 [/SUP], David Meaux[SUP] 2 [/SUP], Tristan Long[SUP] 2 [/SUP], Derek Saccoccio[SUP] 2 [/SUP], Stephan Moll[SUP] 4 [/SUP]
Affiliations
- PMID: 33733027
- PMCID: PMC7938613
- DOI: 10.1002/rth2.12485
Abstract
Background: Coronavirus disease 2019 (COVID-19) is associated with high rates of thromboembolic events in hospitalized patients. It remains to be determined if this risk persists following hospital discharge.
Methods: We conducted a retrospective cohort study of outpatients recently hospitalized for COVID-19 to determine the incidence of vascular thromboembolic events within 30 days of discharge. We investigated the risk factors associated with these events, including intensive care admission, age, and anticoagulation.
Results: Among 447 patients hospitalized for COVID-19, 2.0% experienced a vascular thromboembolic event within 30 days of discharge. No risk factor variable was significantly associated with an increased risk for these events.
Conclusions: The incidence of vascular thromboembolic events following hospital discharge for COVID-19 is low. These findings suggest against the routine use of postdischarge thromboprophylaxis in patients with COVID-19.
Keywords: COVID?19; anticoagulant; discharge; outpatients; thromboembolism.